ADITEC partner TBVI has opened a call for proposals for early clinical development of new, promising TB vaccines.
This call focuses on support for cGMP manufacturing, toxicity and safety evaluation of new promising vaccine candidates, and/or support for carrying out (first in human) phase I clinical trials. Proposals must demonstrate complementarity and novelty of the vaccine candidate as compared to the current global vaccine pipeline. Vaccine candidates targeting HIV-uninfected adolescents and young adults, and/or candidates with promise as transmission blocking vaccine will have priority.
Available budget for this call: US$ 780,000. TBVI will contribute up to a maximum of 75% of the total funding (25% co-funding of total cost must be identified in the application)
Deadline for proposals: 17:00 CEST, 11 September 2012
More information can be found on the website of TBVI.